1720 Stock Overview
Standard Chemical & Pharmaceutical Co. Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Standard Chemical & Pharmaceutical Co. Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$62.00 |
| 52 Week High | NT$79.40 |
| 52 Week Low | NT$60.00 |
| Beta | 0.14 |
| 1 Month Change | 1.81% |
| 3 Month Change | -2.05% |
| 1 Year Change | -9.36% |
| 3 Year Change | 44.69% |
| 5 Year Change | 81.82% |
| Change since IPO | 185.62% |
Recent News & Updates
Standard Chemical & Pharmaceutical (TWSE:1720) Is Increasing Its Dividend To NT$2.70
Jul 29
Standard Chemical & Pharmaceutical (TWSE:1720) Will Pay A Larger Dividend Than Last Year At NT$2.70
Jul 14Recent updates
Standard Chemical & Pharmaceutical (TWSE:1720) Is Increasing Its Dividend To NT$2.70
Jul 29Standard Chemical & Pharmaceutical (TWSE:1720) Will Pay A Larger Dividend Than Last Year At NT$2.70
Jul 14If You Like EPS Growth Then Check Out Standard Chem & Pharm (TPE:1720) Before It's Too Late
Apr 13A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)
Mar 14Does Standard Chem & Pharm (TPE:1720) Have A Healthy Balance Sheet?
Mar 01Should Standard Chem & Pharm (TPE:1720) Be Disappointed With Their 11% Profit?
Feb 16
Is Standard Chem & Pharm CO., LTD.'s (TPE:1720) 4.3% Dividend Worth Your Time?
Feb 03Standard Chem & Pharm CO., LTD.'s (TPE:1720) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Jan 19Here's Why I Think Standard Chem & Pharm (TPE:1720) Might Deserve Your Attention Today
Jan 04Is Standard Chem & Pharm CO., LTD. (TPE:1720) Popular Amongst Insiders?
Dec 22A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)
Dec 08Standard Chem & Pharm (TPE:1720) Seems To Use Debt Rather Sparingly
Nov 26Shareholder Returns
| 1720 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 0.3% | 3.5% | -1.3% |
| 1Y | -9.4% | 8.3% | 22.0% |
Return vs Industry: 1720 underperformed the TW Pharmaceuticals industry which returned 8.3% over the past year.
Return vs Market: 1720 underperformed the TW Market which returned 22% over the past year.
Price Volatility
| 1720 volatility | |
|---|---|
| 1720 Average Weekly Movement | 1.9% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 1720 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1720's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | n/a | Tzu-Ting Fan | www.standard.com.tw |
Standard Chemical & Pharmaceutical Co. Ltd. engages in the manufacture and sale of pharmaceutical products, supplements, and APIs in Taiwan and internationally. The company offers various pharmaceutical products for metabolic, respiratory, musculoskeletal, digestive, circulatory system, topical dermatological, cardiovascular system, anti-infectives, urogenital system and sex hormones, and others.
Standard Chemical & Pharmaceutical Co. Ltd. Fundamentals Summary
| 1720 fundamental statistics | |
|---|---|
| Market cap | NT$11.08b |
| Earnings (TTM) | NT$847.58m |
| Revenue (TTM) | NT$6.71b |
13.1x
P/E Ratio1.7x
P/S RatioIs 1720 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1720 income statement (TTM) | |
|---|---|
| Revenue | NT$6.71b |
| Cost of Revenue | NT$3.77b |
| Gross Profit | NT$2.94b |
| Other Expenses | NT$2.09b |
| Earnings | NT$847.58m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.74 |
| Gross Margin | 43.81% |
| Net Profit Margin | 12.63% |
| Debt/Equity Ratio | 6.0% |
How did 1720 perform over the long term?
See historical performance and comparisonDividends
4.4%
Current Dividend Yield57%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/15 05:24 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Standard Chemical & Pharmaceutical Co. Ltd. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Qing Rong Lin | E.Sun Securities Investment Consulting Co. Ltd. |
| Regina Lee | IBTS Investment Consulting Co., Ltd. |
| Li-chun Chang | Jih Sun Securities Investment Consulting Co., Ltd. |